LS&HC Horizons 2022 - Flipbook - Page 57
9
Europe
Early access in early launch markets France and Germany
58
The European Commission’s revision of EU pharmaceutical
law, in particular relating to regulatory data protection and
market exclusivity
59
Hospital exemption for academic gene and cell therapies
in the EU
60
Reimbursement of digital health applications
in Europe
61
New pitfalls in EU pharma supply chain
62
Proposed reform of UK medical devices regulation
63
ESG on the horizon - What do supply chain regulations and
litigation trends mean for the sector?
64
